Sanofi India
Ticker > Company >

Sanofi India share price

Sanofi India Ltd.

NSE: SANOFI BSE: 500674 SECTOR: Pharmaceuticals & Drugs  1.4 L   377   50

4750.10
-131.95 (-2.70%)
BSE: 26 Sep 04:01 PM

Price Summary

Today's High

₹ 4894.8

Today's Low

₹ 4732

52 Week High

₹ 7249.9

52 Week Low

₹ 4145.9

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 10939.78 Cr.

Enterprise Value

₹ 10644.98 Cr.

No. of Shares

2.3 Cr.

P/E

30.18

P/B

13.99

Face Value

₹ 10

Div. Yield

2.46 %

Book Value (TTM)

₹  339.6

CASH

₹ 294.8 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

60.4 %

EPS (TTM)

₹  157.4

Sales Growth

0.86%

ROE

36.09 %

ROCE

46.15%

Profit Growth

-13.96 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Sanofi India Ltd.

Allegra Avil Combiflam Clexane Cardace Daonil Lantus Taxotere Soframycin Arava Lasix

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0.86%
3 Year-12.02%
5 Year-8.1%

Profit Growth

1 Year-31.45%
3 Year-24.07%
5 Year-0.03%

ROE%

1 Year36.09%
3 Year35.52%
5 Year34.52%

ROCE %

1 Year46.15%
3 Year47.3%
5 Year45.93%

Debt/Equity

0

Price to Cash Flow

23.69

Interest Cover Ratio

288.6

CFO/PAT (5 Yr. Avg.)

0.831011797566981

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 60.40 0.00
Mar 2025 60.40 0.00
Dec 2024 60.40 0.00
Sep 2024 60.40 0.00
Jun 2024 60.40 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 35.5237247048031% over the past 3 years.
  • Company has been maintaining healthy ROCE of 47.2980759715162% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 288.6.
  • The Company has been maintaining an effective average operating margins of 24.339893192051% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 4.83409999999998 days.
  • The company has a high promoter holding of 60.4%.

 Limitations

  • The company has shown a poor profit growth of -30.744726809993% for the Past 3 years.
  • The company has shown a poor revenue growth of -12.0237716281358% for the Past 3 years.
  • The company is trading at a high PE of 30.18.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 463.5 524 514.9 535.9 406.3
Total Expenditure 347.8 404.3 396.6 364 311.4
Operating Profit 115.7 119.7 118.3 171.9 94.9
Other Income 4.8 2.3 5.9 3.3 8.7
Interest 0.4 0.4 0.4 0.3 0.4
Depreciation 9 9 9.6 9.6 9.1
Exceptional Items -19 0 8 0 0
Profit Before Tax 92.1 112.6 122.2 165.3 94.1
Tax 23.9 30.4 30.9 45.8 24.6
Profit After Tax 68.2 82.2 91.3 119.5 69.5
Adjusted EPS (Rs) 29.65 35.74 39.7 51.96 30.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024
Net Sales 2901.9 2956.6 2770.1 1996.1 2013.2
Total Expenditure 2188.8 2194.3 2067.2 1509 1522.9
Operating Profit 713.1 762.3 702.9 487.1 490.3
Other Income 89.8 74.6 73 61.8 17
Interest 1.8 1.8 1.7 1.7 1.5
Depreciation 82.2 66.7 41.9 36.5 36.7
Exceptional Items -41.7 489.2 132 17.8 -37.7
Profit Before Tax 677.2 1257.6 864.3 528.5 431.4
Tax 199.6 313.2 243.7 163.9 117.7
Net Profit 477.6 944.4 620.6 603.2 413.5
Adjusted EPS (Rs.) 207.65 410.61 269.83 158.52 136.39

Balance Sheet (All Figures are in Crores.)

Particulars Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024
Equity and Liabilities
Share Capital 23 23 23 23 23
Total Reserves 2096 2202.6 1252.8 992.5 837.6
Borrowings 0 0 0 0 0
Other N/C liabilities 1280.3 1038.9 808.7 1152.9 1208.4
Current liabilities 1694.1 2289.9 2742.5 2534.8 2610.1
Total Liabilities 5093.4 5555.3 4827.9 4703.2 4679.1
Assets
Net Block 464.1 334.1 305.5 314.9 312.5
Capital WIP 6.3 8.9 18.8 13.3 18.1
Intangible WIP 3.7 3.9 4.8 2.6 0
Investments 0 0 0 2 0
Loans & Advances 1773.1 1521.4 877.7 1233.2 1324.6
Other N/C Assets 5.6 11.8 9 7.4 6.2
Current Assets 2840.6 3675.2 3612.1 3129.8 3017.7
Total Assets 5093.4 5555.3 4827.9 4703.2 4679.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024
Profit from operations 677.2 1257.6 864.3 845.8 562.6
Adjustment 65 -482 -159.3 -24.8 25.1
Changes in Assets & Liabilities 62.2 68.1 -45.6 -348.9 -28.6
Tax Paid -193.3 -284.9 -260.7 -241.3 -97.4
Operating Cash Flow 611.1 558.8 398.7 230.8 461.7
Investing Cash Flow 276.4 630.8 650.9 35.5 -178.4
Financing Cash Flow -810 -849 -1582.7 -878.3 -392.4
Net Cash Flow 77.5 340.6 -533.1 -612 -109.1

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 60.40 60.40 60.40 60.40 60.40
hoechst gmbh 60.37 60.37 60.37 60.37 60.37
sanofi 0.02 0.02 0.02 0.02 0.02
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 39.60 39.60 39.60 39.60 39.60
aditya birla sun life tru... 3.25 2.63 2.61 2.77 2.80
bajaj allianz life insura... 1.60 1.56 1.56 1.38 1.37
general insurance corpora... 1.43 1.58 2.18 2.49 2.56
hdfc life insurance compa... - 1.45 1.47 1.47 1.47
investor education and pr... - 0.19 0.21 - 0.21
life insurance corporatio... - 5.95 5.95 5.95 5.95
llp 0.05 0.04 0.04 0.04 0.04
nippon life india trustee... 3.90 3.87 3.88 3.88 3.72
sbi magnum midcap fund - 3.10 - 3.57 3.57
investor education and pr... 0.19 - - 0.21 -
sbi nifty smallcap 250 in... - - 3.11 - -
hdfc life insurance compa... 1.39 - - - -
life insurance corporatio... 5.95 - - - -
sbi contra fund 1.80 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2022
Annual Report 2021
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY24
Concall Q3FY24
Concall Q3FY23
Concall Q2FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23

Company News

Sanofi India - Quaterly Results 31 Jul, 6:47 PM Sanofi India - Quaterly Results 31 Jul, 6:47 PM Sanofi India - Quaterly Results 31 Jul, 6:47 PM Sanofi India informs about board meeting 18 Jul, 4:50 PM Sanofi India informs about change in management 24 May, 4:05 PM Sanofi India - Quaterly Results 14 May, 5:34 PM Sanofi India - Quaterly Results 14 May, 5:34 PM Sanofi India - Quaterly Results 14 May, 5:34 PM Sanofi India informs about disclosure 25 Apr, 3:29 PM Sanofi India informs about disclosure 24 Apr, 12:41 PM Sanofi India informs about press release 16 Apr, 5:12 PM Sanofi India informs about compliance certificate 9 Apr, 5:36 PM Sanofi India informs about disclosure 13 Mar, 4:31 PM Sanofi India informs about press release 1 Mar, 4:13 PM Sanofi India informs about disclosure 28 Feb, 3:52 PM Sanofi India - Quaterly Results 27 Feb, 9:48 PM Sanofi India - Quaterly Results 27 Feb, 9:48 PM Sanofi India - Quaterly Results 7 Nov, 6:02 PM Sanofi India - Quaterly Results 7 Nov, 6:02 PM Sanofi India - Quaterly Results 7 Nov, 6:02 PM Sanofi India informs about details of loss of certificate 1 Aug, 2:53 PM Sanofi India - Quaterly Results 26 Jul, 3:32 PM Sanofi India - Quaterly Results 26 Jul, 3:32 PM Sanofi India - Quaterly Results 26 Jul, 3:32 PM Sanofi India informs about change in management 24 Jun, 4:20 PM Sanofi India - Quaterly Results 13 May, 7:03 PM Sanofi India - Quaterly Results 13 May, 7:03 PM Sanofi India enters into partnership with Cipla 27 Mar, 11:42 AM Sanofi India informs about loss of share certificate 12 Mar, 5:20 PM Sanofi India informs about loss of share certificates 11 Mar, 12:12 PM Sanofi India informs about outcome of analyst meet 26 Feb, 5:15 PM Sanofi India - Quaterly Results 23 Feb, 6:08 PM Sanofi India - Quaterly Results 23 Feb, 6:08 PM Sanofi India - Quaterly Results 23 Feb, 6:08 PM Sanofi India informs about newspaper publication 20 Feb, 4:37 PM Sanofi India informs about loss of share certificates 1 Feb, 12:03 PM Sanofi India informs about newspaper publication 16 Jan, 5:13 PM Sanofi India informs about disclosure 29 Nov, 12:29 PM Sanofi India - Quaterly Results 8 Nov, 5:35 PM Sanofi India - Quaterly Results 8 Nov, 5:35 PM Sanofi India submits board meeting intimation 19 Oct, 4:49 PM Sanofi India informs about change in management 17 Oct, 12:40 PM Sanofi India informs about investor awareness on ODR mechanism 23 Sep, 4:22 PM Sanofi India informs about issuance of duplicate share certificates 22 Aug, 2:30 PM Sanofi India - Quaterly Results 10 Aug, 3:56 PM Sanofi India - Quaterly Results 10 Aug, 3:56 PM Sanofi India - Quaterly Results 10 Aug, 3:56 PM Sanofi India informs about board meeting 26 Jul, 2:40 PM Sanofi India informs about resignation of non-executive director 20 Jul, 12:36 PM Sanofi India informs about issuance of duplicate share certificates 19 Jul, 4:46 PM

Sanofi India Stock Price Analysis and Quick Research Report. Is Sanofi India an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sanofi India. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sanofi India has a PE ratio of 30.1685333651844 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sanofi India has ROA of 6.6871% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sanofi India has a Current ratio of 1.1562.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sanofi India has a ROE of 36.0927%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sanofi India has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sanofi India has reported revenue growth of 0.8567% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sanofi India for the current financial year is 24.3542618716471%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sanofi India is Rs 117 and the yield is 2.4631%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sanofi India is Rs 157.3991. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sanofi India in Ticker for free. Also, one can get the intrinsic value of Sanofi India by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sanofi India FAQs

Q1. What is Sanofi India share price today?
Ans: The current share price of Sanofi India is Rs 4748.5.

Q2. What is the market capitalisation of Sanofi India?
Ans: Sanofi India has a market capitalisation of Rs 10936.0908567 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sanofi India?
Ans: The PE ratio of Sanofi India is 30.1685333651844 and the P/B ratio of Sanofi India is 13.9824372225818, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sanofi India share?
Ans: The 52-week high share price of Sanofi India is Rs 7248.75, and the 52-week low share price of Sanofi India is Rs 4865.5.

Q5. Does Sanofi India pay dividends?
Ans: Currently, Sanofi India pays dividends. Dividend yield of Sanofi India is around 2.4631%.

Q6. What are the face value and book value of Sanofi India shares?
Ans: The face value of Sanofi India shares is Rs 10, while the book value per share of Sanofi India is around Rs 339.6046. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sanofi India?
Ans: Sanofi India has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sanofi India?
Ans: The ROE of Sanofi India is 36.0927% and ROCE of Sanofi India is 46.1489%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sanofi India a good buy for the long term?
Ans: The Sanofi India long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sanofi India undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sanofi India appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sanofi India’s financials?
Ans: You can review Sanofi India’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sanofi India

Sanofi India Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

Sanofi India Ltd Share Price

 

Sanofi India Ltd. is a pharmaceutical company operating in India. In this section, we will analyze the share price performance of Sanofi India Ltd. Ticker pre-built screening tools provide investors with real-time updates on the share price movements of the company.

Sanofi India Ltd Balance Sheet

Analyzing the balance sheet of Sanofi India Ltd. is crucial for long-term stock investors. It helps in understanding the financial position of the company. However, we do not provide specific financial data points about the stock. You can access the balance sheet of Sanofi India Ltd. on Ticker for a comprehensive analysis.

Sanofi India Ltd Annual Report

The annual report of Sanofi India Ltd. is a valuable resource for investors looking to analyze the company's performance over the years. You can download the annual report from Ticker to gain insights into the company's operations, financials, and future prospects.

Sanofi India Ltd Dividend

Investors seeking long-term investment opportunities often consider dividends as an important factor. Sanofi India Ltd. has a track record of consistent dividend payments. You can find more information about the dividend history and yield of Sanofi India Ltd. on Ticker.

Sanofi India Ltd Quarterly Result

Analyzing the quarterly results of Sanofi India Ltd. provides investors with the latest information on the company's financial performance. Ticker offers downloadable quarterly results, allowing investors to stay updated with the latest developments and make informed decisions.

Sanofi India Ltd Stock Price

Tracking the stock price of Sanofi India Ltd. is essential for investors. Ticker provides real-time stock price information, enabling investors to monitor fluctuations and make timely investment decisions. You can also access historical price charts to analyze the stock's performance over time.

Sanofi India Ltd Price Chart

The price chart of Sanofi India Ltd. shows the historical performance of the stock. By visually analyzing the price movements, investors can identify patterns and trends that may guide their investment decisions. You can access the price chart on Ticker for a comprehensive stock analysis.

Sanofi India Ltd News

Staying updated with the latest news and developments related to Sanofi India Ltd. is crucial for investors. Ticker provides a dedicated news section where you can find the latest updates, market trends, and announcements regarding Sanofi India Ltd.

Sanofi India Ltd Concall Transcripts

Concall transcripts provide valuable insights into the company's performance and management's outlook. At Ticker, you can access the concall transcripts of Sanofi India Ltd., allowing investors to understand the discussions held during the conference calls and gain deeper insights into the company's strategies.

Sanofi India Ltd Investor Presentations

Investor presentations offer an in-depth understanding of Sanofi India Ltd.'s business strategies, financials, and future prospects. Ticker provides access to investor presentations, enabling investors to make informed investment decisions based on comprehensive information.

Sanofi India Ltd Promoters

Understanding the promoters of a company is crucial for investors. The promoters of Sanofi India Ltd. play a significant role in the company's operations and decision-making. You can find information about the promoters of Sanofi India Ltd. on Ticker.

Sanofi India Ltd Shareholders

Analyzing the shareholder structure of Sanofi India Ltd. provides insights into the ownership pattern and the distribution of shares. Ticker offers details on the major shareholders of Sanofi India Ltd., helping investors understand the dynamics of ownership within the company.

Sanofi India Ltd ROCE

Sanofi India Ltd's Return on Capital Employed (ROCE) is a crucial financial metric that measures the company's profitability and efficiency in utilizing capital investments. Our stock analysis page provides comprehensive ROCE data for Sanofi India Ltd, allowing investors to evaluate the company's ability to generate returns from the capital employed. By analyzing this ratio, investors can gain insights into the company’s financial performance. Access the detailed ROCE information for Sanofi India Ltd in the financials table or ratio section on this page.

Sanofi India Ltd EBITDA

Sanofi India Ltd's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a key measure for assessing the company's operational performance and profitability. Our stock analysis page provides comprehensive EBITDA data for Sanofi India Ltd, enabling investors to evaluate the company's core earnings and financial health. Access the detailed EBITDA figures for Sanofi India Ltd in the financials table or ratio section on this page.

Sanofi India Ltd DPS

Sanofi India Ltd's Dividends Per Share (DPS) reflect the portion of profits distributed to shareholders as dividends. Monitoring DPS is crucial for investors seeking a consistent income from dividends. Our stock analysis page features the DPS data for Sanofi India Ltd, enabling investors to track the company's dividend history and payout ratio. Access the detailed DPS information for Sanofi India Ltd in the financials table or ratio section on this page.

Sanofi India Ltd EPS

Earnings Per Share (EPS) is a fundamental financial metric that measures Sanofi India Ltd's profitability on a per-share basis. Our stock analysis page provides detailed EPS information for Sanofi India Ltd, allowing investors to evaluate the company's earnings performance and growth potential. Access the comprehensive EPS figures for Sanofi India Ltd in the financials table or ratio section on this page to make informed investment decisions. 

Sanofi India Reserves Analysis

When assessing the financial health of Sanofi India, a key area of focus is the company's reserves. From December 2019 to December 2023, there has been a visible decrease in total reserves, from Rs 2,419.30 Cr to Rs 992.50 Cr. This could indicate the company has been utilizing reserves for investments, paying off debts, or distributing dividends.

Sanofi India Balance Sheet Overview

Sanofi India's balance sheet showcases stability with no borrowings from December 2019 to December 2023, reflecting a debt-free position. However, the total liabilities have seen fluctuations, indicating changes in other non-current and current liabilities. The total liabilities decreased from Rs 5,239.90 Cr in December 2019 to Rs 4,703.10 Cr by December 2023.

Sanofi India Debt Profile

Remarkably, Sanofi India has maintained a borrowing figure at zero throughout the observed period. The absence of debt on Sanofi India's balance sheet is an encouraging sign for investors looking for a company with minimal financial risk.

Sanofi India Asset Formation

The asset structure of Sanofi India has transformed over the years, with a gradual dip in net block from Rs 498.70 Cr in December 2019 to Rs 314.90 Cr in December 2023, suggesting a possible depreciation or asset disposal strategy. The current assets though reduced in the last year, still reflect a robust figure standing at Rs 3,129.70 Cr.

This analysis is framed on the standalone balance sheet of Sanofi India, providing insights for investors and market participants. It should be noted that balance sheets are just one of many tools that investors can use alongside other financial information and market indices such as NSE and BSE, sectoral performance, IPOs, and stock screenings to make informed decisions.

Read More
X